FY2025 · ended Dec 31, 2025 · Revenue $79.95M, +104.9% YoY · Filed Mar 19, 2026
Eton Pharmaceuticals, Inc. (ETON) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $80.0 million and a net loss of $4.6 million. Free cash flow was $10.2 million. As of Jun 30, 2026 it held $26.8 million in cash and investments and $20.4 million in total debt.
Revenue (TTM)
$105.59M
+81.5% vs year-ago TTM
Net income (TTM)
$12.69M
+407.4% vs year-ago TTM
Operating cash flow (TTM)
$15.13M
+23.7% vs year-ago TTM
Free cash flow (TTM)
$14.73M
+20.5% vs year-ago TTM
EPS
—
Dividend per share
None
Shares outstanding
27.28M
+1.7% vs prior year
Net cash
$6.45M
as of Jun 30, 2026
Operating margin
15.4%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ETON (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Deer Park, IL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1710340
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $80.0M | $39.0M | $31.6M | $21.3M | $21.8M |
| Operating income | -$844,000 | -$2.6M | -$1.2M | -$8.3M | -$1.5M |
| Net income | -$4.6M | -$3.8M | -$936,000 | -$9.0M | -$2.0M |
| Operating cash flow | $10.5M | $969,000 | $6.8M | $4.8M | -$4.7M |
| Free cash flow | $10.2M | $943,000 | $6.8M | $4.8M | -$4.7M |
| Total assets | $92.1M | $76.1M | $31.7M | $25.0M | $27.5M |
| Total liabilities | $66.0M | $51.7M | $16.3M | $12.0M | $9.8M |
| Stockholders' equity | $26.2M | $24.4M | $15.5M | $13.1M | $17.6M |
| Cash and investments | $25.9M | $14.9M | $21.4M | $16.3M | $14.4M |
| Total debt | $31.1M | $30.0M | $5.5M | $5.6M | $5.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Other events
|
Sep 28, 2026 | Sep 28, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets
|
Aug 5, 2026 | Jul 31, 2026 |
All 418 Eton Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.